BioSpace News Archive

Resonetics announced today that it has acquired EaglePicher Technologies’ Medical Power business, a leading manufacturer of implantable batteries for critical medical devices based near Vancouver, British Columbia.

“We started 2022 with key service provider partnerships and positioned in high potential properties that will drive growth in user engagement and revenue,” stated Mark Holmes, CEO of Zonetail.

Jackson Center, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Halberd Corporation (OTC PINK: HALB) announces plans to enter the Metaverse by the creation of non-fungible tokens (NFT’s) to monetize certain intellectual properties of the company including but not limited to patents, patents pending, trade secrets, etc.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the appointment of James Gruber as Chief Financial Officer, effective immediately.

BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”), a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”), announced today that it has entered into a research collaboration with Janssen Biotech, Inc., one of the Pharmaceutical Companies of Johnson & Johnson.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, tomorrow on April 12 will present a poster on its FAP-Alpha targeted program PNT2004 at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced it has commenced an underwritten public offering.

Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), today shared additional data from the PEACE Phase 3 study during a poster presentation at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting being held in Orlando, FL from April 10-13.

Stealth BioTherapeutics Corp today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase in a registered direct offering 5,583,028 American Depositary Shares.